Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Assessing Family Caregiver Readiness for Hospital Discharge of Patients With Serious or Life‐Limiting Illness Using Electronic Health Record and Self‐Reported Data
Griffin, Joan M. , Holland, Diane E. , Vanderboom, Catherine E., Kaufman, Brystana G. , Gustavson, Allison M. , Ransom, Jeanine E. , Mandrekar, Jay , Dose, Ann Marie , Ingram, Cory , Wild, Ellen, Ransom, Jeanine, Weiss, Marianne E , Griffin, Joan M , Fong, Zhi Ven

Health Services Research | January 28, 2025 | Volume: 60 | Issue: 4 | Pages: No page available

10.1111/1475-6773.14441 | PMID 39871699 Get It

ABSTRACTObjectiveTo assess how patient and caregiver factors influence caregiver readiness for hospital discharge in palliative care patients.Study Setting and DesignThis transitional care study uses cross‐sectional data from a randomized controlled trial conducted from 2018 to 2023 testing an intervention for caregivers of hospitalized adult patients with a serious or life‐limiting illness who received a palliative care consult prior to transitioning out of the hospital.Data Sources and Analytical SampleCaregiver readiness was measured with the Family Readiness for Hospital Discharge Scale (n = 231). Caregiver demographic, intra‐ and interpersonal factors were self‐reported. Patient demographic, comorbidity score, and risk score for complicated discharge planning were extracted from electronic health records. Stepwise regression models estimated variance explained (r2) in caregiver readiness for patient hospital discharge.Principal FindingsPatient demographics and complexity were not statistically associated with caregiver readiness for discharge. Caregiver depressive symptoms, poor caregiver‐patient relationship quality, and fewer hours spent caregiving prior to hospitalization explained 29% of the variance in caregiver readiness.ConclusionsReliance on patient data may not be sufficient for explaining caregiver readiness for discharge. Assessing caregiver factors may be a better alternative for identifying caregivers at risk for low discharge readiness and those in need of additional support.Trial Registration: ClinicalTrials.gov on November 13, 2017, (No. NCT03339271)
Resolution of Iatrogenic Spinal Accessory Neuropathy Following Delayed Surgical Intervention
Qu, Yihuai , Entezami, Payam , Cave, Taylor B., Klusovsky, Laura E., Chang, Brent A. , Chang, Brent A

The Laryngoscope | January 28, 2025 | Volume: 135 | Issue: 6 | Pages: 2073-2075

10.1002/lary.32012 | PMID 39871412 Get It

We present an interesting case of a 74‐year‐old female who presented with spinal accessory neuropathy following an ipsilateral right‐sided carotid endarterectomy 6 months after the initial injury. Subsequent surgical exploration revealed a surgical clip that had been placed directly across the spinal accessory nerve. Clip removal and neurolysis was subsequently performed, leaving the nerve intact. After surgical intervention, she immediately demonstrated increased bilateral shoulder shrug motion and continues to improve her function with physical therapy. This case demonstrates a fascinating case of cranial nerve recovery after delayed intervention in the context of existing literature. Laryngoscope, 135:2073–2075, 2025
Toward Activity and Chronicity Indices for the Evaluation of Kidney Transplant Rejection: A Viewpoint by the Banff Working Group
Cornell, Lynn D. , Seshan, Surya V. , Cornell, Lynn , Naesens, Maarten , Haas, Mark

Transplantation | January 28, 2025 | Volume: 109 | Issue: 6 | Pages: 915-919

10.1097/tp.0000000000005336 | PMID 39883028 Get It

Validation of a Pretransplant Risk Prediction Model for Early Allograft Dysfunction After Living-donor Liver Transplantation
Gunasekaran, Vasanthakumar , Chen, I. , Marquez, Kris Ann Hervera , Hsu, Shih-Chao, Akamatsu, Nobuhisa , Shaked, Oren , Genedy, Lara, Yebyo, Henock G. , Dutkowski, Philipp , Boehnert, Markus , Mathur, Abhishek , Emond, Jean C. , Testa, Giuliano , Olthoff, Kim M. , Rosen, Charles B. , Taner, Timuçin , Wong, Tiffany , Lo, Chung‐Mau, Cattral, Mark S. , Sapisochin, Gonzalo, Jeng, Long‐Bin , Chen, Chao‐Long , Rela, Mohamed , Bröering, Dieter C. , Clavien, Pierre‐Alain , Li, Zhihao , Yeow, Marcus, Hsu, Shih-Chao , Li, Zhihao , Akamatsu, Nobuhisa , Wong, Tiffany C L , Li, Zhihao, Raptis, Dimitri , Rammohan, Ashwin , Hong, Su young , Kim, Jong Man , Kirimker, Elvan Onur , Finotti, Michele , Yeow, Marcus , Braun, Julia , Nadalin, Silvio , Polak, Wojciech G. , Bonney, Glenn Kunnath , Samstein, Benjamin , Heimbach, Julie K. , Hasegawa, Kiyoshi , Balci, Deniz , Sapisochín, Gonzalo , Selzner, Nazia , Joh, Jae-Won , Suh, Kyung-Suk

Transplantation | January 28, 2025 | Volume: 109 | Issue: 8 | Pages: 1383-1392

10.1097/tp.0000000000005331 | PMID 39883022 Get It

Background. Early allograft dysfunction (EAD) affects outcomes in liver transplantation (LT). Existing risk models developed for deceased-donor LT depend on posttransplant factors and fall short in living-donor LT (LDLT), where pretransplant evaluations are crucial for preventing EAD and justifying the donor’s risks. Methods. This retrospective study analyzed data from 2944 adult patients who underwent LDLT at 17 centers between 2016 and 2020. We developed a logistic regression model to predict EAD based on this development cohort. We used data from 1020 patients at the King Faisal Transplant Center for external validation. Results. In the development cohort, 321 patients (10.9%) experienced EAD. These patients had poorer health status, more liver decompensation, and higher requirements of hospitalization than those without EAD. Multivariable logistic regression identified independent pretransplant predictors of EAD: laboratory Model for End-Stage Liver Disease score (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.06-1.09), the necessity for hospitalization at the time of transplant (OR, 2.58; 95% CI, 2.00-3.30), and graft weight in kilogram (OR, 0.27; 95% CI, 0.17-0.45). Using these predictors, we developed the model for EAD after LDLT, which demonstrated strong discriminative ability in the development cohort with an area under the curve (AUC) of 0.71 (95% CI, 0.68-0.74). The model maintained high discrimination during internal validation (AUC, 0.70; 95% CI, 0.67-0.73) and showed a modest reduction in discriminative power in external validation (AUC, 0.65; 95% CI, 0.61-0.68). Conclusions. EAD post-LDLT is influenced by the recipient’s pretransplant health condition and the graft weight. Integrating the model for EAD after LDLT into the pretransplant process of pairing donors and recipients can enhance the safety and efficacy of LDLT.
Patient Perceptions of an Intervention for Cancer Distress and Traumatic Stress Symptoms: A Qualitative Analysis
Rhudy, Lori M. , Donovan, Kristine A. , Foster, Renee, Spaulding, Aaron , Niazi, Shehzad K. , Tofthagen, Cindy , Niazi, Shehzad, Tofthagen, Cindy S , Spaulding, Aaron , Perlman, Adam

Clinical Nursing Research | January 27, 2025 | Volume: 34 | Issue: 2 | Pages: 71-78

10.1177/10547738241301895 | PMID 39862130 Get It

This study aimed to explore contextual elements of the cancer experience that are consistently distressing and/or psychologically traumatic, as well as explore perceptions of Accelerated Resolution Therapy® (ART®) and its influence on the cancer experience. Using a qualitative descriptive design, semi-structured interviews were completed by 12 participants following the completion of ART. Interview data were analyzed using content analysis to identify major themes and patterns. Four themes included: (a) Cancer as the straw that broke the camel’s back, (b) ART® is different from previous therapy, (c) Don’t need to always be looking in the rearview mirror, and (d) Importance of early psychological intervention. Participants perceived that ART® was different and potentially more effective than other types of therapy they had previously received. Results support the diagnosis of cancer and the cumulative effects of previous life events and cancer-related stressors as traumatic events.
The Slow Progress in Developing Better Long-Term Cardiovascular Risk Assessment in Women Continues
Jaffe, Allan S. , Donato, Leslie J. , Lara-Breitinger, Kyla M , Jaffe, Allan S.

Clinical Chemistry | January 27, 2025 | Volume: 71 | Issue: 5 | Pages: 535-537

10.1093/clinchem/hvaf003 | PMID 39928360 Get It

Systematic Review of Swarm Intelligence for Autonomous Radiotherapy Planning Decision-Making
Edralin, Sabrina , Xu, Clark , Simasiku, Akebu, Papakostaas, George A., Yue, Zongliang , Priniotakis, Georgios , Gerolimos, Nikitas , Alevizos, Vasileios , Yue, Zongliang , Edralin, Sabrina , Xu, Clark

2024 IEEE 16th International Conference on Computational Intelligence and Communication Networks (CICN) | January 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: 1175-1178

10.1109/cicn63059.2024.10847419 Get It

CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity
Segal‬‏, Yahel , Mangioris, Georgios , Lennon, Vanda A. , Yang, Binxia , Dubey, Divyanshu , McKeon, Andrew , Mills, John R. , Tolédano, Michel B. , Vodopivec, Ivana, Pittock, Sean J. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Pittock, S J , Lennon, Vanda, McKeon, Andrew , Zekeridou, Anastasia , Dubey, Divyanshu , Yang, Binxia , Flanagan, Eoin P. , Toledano, Michel, Segal, Yahel

Annals of Clinical and Translational Neurology | January 27, 2025 | Volume: 12 | Issue: 4 | Pages: 855-860

10.1002/acn3.52305 | PMID 39869499 Get It

AbstractDefining the CSF cytokine/chemokine and injury biomarker signature of glial fibrillary acidic protein (GFAP) autoimmunity can inform immunopathogenesis. CSF GFAP‐IgG‐positive samples (N = 98) were tested for 17 cytokines/chemokines, neurofilament light chain (NfL), and GFAP (ELLA, Bio‐Techne). Controls included non‐inflammatory (N = 42), AQP4‐IgG‐positive (N = 83), CNS infections (N = 13), and neurosarcoidosis (N = 32). IL5, IL6, IL10, IL8/CXCL8, CXCL9, CXCL10, CXCL13, BAFF, GM‐CSF, IFN‐gamma, and TNF‐alpha concentrations were higher compared to non‐inflammatory controls (P < 0.01). GFAP concentrations were similar to those of AQP4‐IgG‐positive patients; NfL was higher (P < 0.001) and correlated with MRI changes and outcomes. CSF cytokine/chemokine findings in GFAP autoimmunity correlate with histopathology; GFAP and NfL hold promise as disease biomarkers.
Phase 1/2 study of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC.
Hecht, J. Randolph, Knecht, John George, Vandross, Andrae Lavon, Perez, Cesar A. , Bessudo, Alberto, Patel, Ekta , Fantini, Damiano , Paramasivan, Sattanathan, Crowe, David, Duncan, Meghan, Davar, Diwakar , Fakih, Marwan , Bekaii‐Saab, Tanios , DeVito, Nicholas C. , Gupta, Anurag Kumar , CROWE, DAVID F. , McConnell, Scott, Luptakova, Katarina , Parikh, Aparna R.

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: 206-206

10.1200/jco.2025.43.4_suppl.206 Get It

206 Background: XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding aCTLA-4 designed to block CTLA-4 and deplete regulatory T cells upon activation in the tumor by proteases. XTX101 also contains mutations designed to enhance Fcγ receptor binding. Fc enhancement augments FcγR co-engagement on antigen presenting cells and has been linked with efficacy of aCTLA-4 combinations in patients (pts) with “cold tumors”, including microsatellite stable (MSS) colorectal cancer (CRC). Parts 1A/1B of the study evaluated XTX101 monotherapy in pts with advanced solid tumors. XTX101 was generally well tolerated with limited peripheral XTX101 activation (~13%) compared to evidence of XTX101 activation in the tumor microenvironment (73-96%, in n=2 on-treatment tumor biopsies). A durable partial response (PR) and resolution of hepatic metastases was observed in a pt with PD-L1 negative NSCLC at the monotherapy recommended phase 2 dose (RP2D) of 150 mg once every six weeks (Q6W) [1]. Methods: Part 1C evaluated the safety and feasibility of XTX101 in combination with atezolizumab in pts with advanced solid tumors using 3+3 dose escalation to establish the RP2D. Phase 2 is enrolling pts with MSS CRC with at least 1 prior regimen for metastatic CRC. Initial safety and anti-tumor activity data from Phase 2 in ~20 pts will be presented. Results: As of July 15, 2024, 15 pts were enrolled in Part 1C: MSS CRC (n=12), esophageal cancer, NSCLC, and ampullary carcinoma (n=1 each). Median age 69 and 3 prior lines of therapy (1-12). Across all XTX101 dose levels (75 mg to 150 mg), treatment-related adverse events (TRAEs) of any grade with >10% incidence included infusion reactions (n=4), fatigue and diarrhea (n=2 each), no G4 or G5 TRAEs were reported. In Part 1C, 2 pts experienced a dose limiting toxicity: 1 pt had G3 colitis, and 1 pt had G3 liver enzyme elevation (both were at the XTX101 150 mg dose level and resolved with immunosuppression). Two unconfirmed PRs were reported: in a pt with MSS CRC, including resolution of a liver target lesion, and in a pt with ampullary carcinoma (accompanied by a Ca 19-9 decrease from 700 to 41). In addition, a decrease in intra-tumoral Tregs was observed in paired tumor biopsies from a pt. The combination RP2D was established as XTX101 100 mg Q6W and atezolizumab 1200 mg once every three weeks (Q3W), and enrollment in the Phase 2 part of the study for pts with MSS CRC is ongoing at the RP2D. Conclusions: In Part 1C dose escalation, the combination of XTX101, a tumor-activated, Fc-enhanced aCTLA-4, and atezolizumab was generally well tolerated in pts with advanced solid tumors and demonstrated initial evidence of anti-tumor activity in cold tumors. These data support the initiation of an ongoing Phase 2 study evaluating the combination in pts with MSS CRC with and without liver metastases. 1. Davar ESMO IO 2023. Clinical trial information: NCT04896697 .
A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study.
Watanabe, Jun, Kotaka, Masahito , Matsuhashi, Nobuhisa , Hirata, Keiji , Aleshin, Alexey , Takemasa, Ichiro , Sato, Akihiro , Taniguchi, Hiroya, Bando, Hideaki , Oki, Eiji , Komatsu, Yoshito , Shiozawa, Manabu , Miyamoto, Yuji , Yeh, Kun‐Huei , Kotani, Daisuke , Misumi, Toshihiro , Nakamura, Yoshiaki , Shi, Qian , Kato, Takeshi , Yoshino, Takayuki

Journal of Clinical Oncology | January 27, 2025 | Volume: 43 | Issue: 4_suppl | Pages: No page available

10.1200/jco.2025.43.4_suppl.lba22 Get It

LBA22 Background: Tumor-informed circulating tumor (ct) DNA testing is recognized as a powerful predictor of CRC recurrence. However, the benefit of systemic therapy to prevent or delay clinical recurrence in patients (pts) with molecular recurrence after curative surgery remains uncertain. Methods: Pts with CRC who had undergone curative resection of primary and/or metastatic sites + standard of care (SoC) adjuvant treatment if applicable, were enrolled in ALTAIR study if they (1) prospectively tested positive for ctDNA using a clinically validated, personalized assay (Signatera™, Natera, Inc.) within 3 months before enrollment and (2) had no recurrence on radiological (CT) imaging. Pts were randomized to receive FTD/TPI or placebo for 6 months. CT and ctDNA analyses were conducted every 2 months in the first year, every 3 months in the second year, and every 6 months in the third year. The primary endpoint was disease-free survival (DFS), with secondary endpoints including ctDNA clearance, overall survival (OS), and adverse events. The study assumed a median DFS of 8 months in the placebo group, an HR of 0.667 for the FTD/TPI group, 0.05 significance level, 0.80 power, 2-year enrollment, and 1-year follow-up, requiring 240 pts and 190 DFS events. Baseline ctDNA levels were evaluated by mean tumor molecules (MTM)/ml. Results: Between July 2020 and June 2023, 243 pts were enrolled and randomized to FTD/TPI (n=122) or placebo (n=121). Baseline characteristics were balanced, and 96.3% of pts received SoC treatment postoperatively. FTD/TPI group had a median DFS of 9.30 months vs. 5.55 months in the placebo group, but this difference did not reach statistical significance in the primary population (HR, 0.79; 95% CI, 0.60-1.05; P = 0.107). The FTD/TPI benefit was highly significant in resected oligometastatic stage IV pts as shown in Table. The baseline MTM/ml levels were significantly higher in resected oligometastatic Stage IV pts vs non-Stage IV (0.68 vs 0.32, P = 0.024). Overall, FTD/TPI benefit was significantly pronounced with higher MTM/mL, with linear benefit observed with increasing MTM/mL values at the enrollment time point. OS data remain immature, with 24 events reported across both arms. Grade ≥3 adverse events occurred in 73.0% of the FTD/TPI arm versus 3.3% in the placebo arm, with no new safety signals. Conclusions: Although statistical significance was not reached in the primary population, FTD/TPI showed clinically meaningful DFS benefit in pts with resected oligometastatic disease and a trend towards increasing DFS benefits with increasing MTM/mL values. Clinical trial information: NCT04457297 . Number Baseline MTM/ml Median DFS FTD/TPI(months) Placebo (months) Primary population 243 0.40 9.30 5.55 HR, 0.79 P = 0.107 Stage IV 66 0.68 9.76 3.96 HR, 0.53 P = 0.012 Non-Stage IV 177 0.32 9.26 6.05 HR, 0.86 P = 0.378